ViroGates and Hellenic Institute for the Study of Sepsis announce positive results from the investigator-sponsored SAVE-MORE randomised controlled trial.

SAVE-MORE is a multicenter, double-blinded, randomised controlled trial in 594 hospitalised patients that specifically identifies those at risk of severe respiratory failure by the measurement of elevated suPAR (soluble urokinase plasminogen activator receptor), a plasma biomarker that reflects immune activation and has been previously associated with poor prognosis in a number of conditions.

Summary of results:

  • Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia
  • 28-day mortality decreased (Hazard ratio: 0.45; P: 0.045)
  • Anakinra-treated patients were distributed to lower strata of WHO-CPS by day 28 (adjusted odds ratio-OR 0.36; 95%CI 0.26-0.50; P<0.001)
  • Anakinra protected from severe disease or death (6 or more points of WHO-CPS) (OR: 0.46; P: 0.01)
  • Hospital stay was shorter

Conclusion

Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.

The study is sponsored by the Hellenic Institute for the Study of Sepsis (HISS) in Greece and led by its President and Chairman, Professor Evangelos J. Giamarellos-Bourboulis. Giamarellos-Bourboulis is Professor of Internal Medicine and Infectious Diseases at the National and Kapodistrian University of Athens, President of the European Shock Society and Chairman of the European Sepsis Alliance.

Attachments

  • Original document
  • Permalink

Disclaimer

ViroGates A/S published this content on 20 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2021 10:39:06 UTC.